Posted by Phillipa on January 27, 2013, at 12:29:48
I thought his was old news what's with Pristique now was it not appoved for Major Depression? And Thought already time release? Phillipa
Medscape Medical News > PsychiatryTopline Phase 4 Results for SNRI Released
Deborah Brauser
Jan 24, 2013
Pfizer has announced positive topline results from a phase 4 efficacy study of the selective serotonin and norepinephrine reuptake inhibitor (SNRI) desvenlafaxine (Pristiq) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.
The multicenter, randomized controlled trial included 924 patients with MDD. Those who received for 8 weeks 50 mg/day of desvenlafaxine and those who received 100 mg/day of the medication showed a significant change from baseline on the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score compared with the participants who received matching placebo.
The HAM-D17 was the study's primary efficacy measure. In addition, the company reports that the most common treatment-related adverse events "were consistent with the known safety and tolerability profile of Pristiq."
Previous research has shown that these effects can include nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, and specific male sexual function disorders.
Steven J. Romano, MD, senior vice president and head of the Medicines Development Group for Pfizer, said in a release that these results add to the growing body of evidence that supports desvenlafaxine as a treatment option for those suffering with MDD.
"We know how challenging it can be to treat and manage major depressive disorder. We continue to study Pristiq in order to provide clinicians with more information that can better guide their treatment decisions," said Dr. Romano.
The investigators note that all of the study results will soon be submitted for publication and for presentation at upcoming scientific meetings.
poster:Phillipa
thread:1036577
URL: http://www.dr-bob.org/babble/20130124/msgs/1036577.html